|
|||||||
 |
A recent review of treatments for Psoriatic arthritis (PsA) found that the benefit of different therapies depended how widespread the disease was. Psoriatic arthritis is the second most common cause of joint inflammation. It involves the skin and joints, but may also affect fingers and toes, eyes and the spine. The effect on the skin is seen [...] Tumor necrosis factor (TNF) has been identified as having a key responsibility in many inflammatory diseases, including rheumatoid arthritis (RA). There has been substantial research into the early signaling pathways activated by TNF, but there is not much known about the delayed and chronic TNF responses. In addition, cells called macrophages (cells within the tissues that originate [...] Biogen Idec Inc. announced on October 9th that it was discontinuing development of its investigational rheumatoid arthritis (RA) drug baminercept after if failed to meet Phase II study endpoints. [...] Earlier this year British researchers raised a concern that anti-TNF drugs, as a result of their action in depressing the immune system, may increase the overall risk of cancer. Spanish researchers who are presenting their research at the American College of Rheumatology’s annual meeting in San Francisco say their studies do not support that conclusion. [...] The first international guidelines for the treatment of psoriatic arthritis has been developed and published by a group of rheumatologists, dermatologists, and patient advocates. [...] |
  
|
|||||
|
Copyright © 2010 Current Arthritis News and Research - All Rights Reserved
|
|||||||
Recent Comments